US20150231098A1 - Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne - Google Patents

Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne Download PDF

Info

Publication number
US20150231098A1
US20150231098A1 US14/421,616 US201314421616A US2015231098A1 US 20150231098 A1 US20150231098 A1 US 20150231098A1 US 201314421616 A US201314421616 A US 201314421616A US 2015231098 A1 US2015231098 A1 US 2015231098A1
Authority
US
United States
Prior art keywords
acne
skin
composition according
composition
exfoliating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/421,616
Inventor
José Agustín Rogelio Magaña Castro
Laura Vázquez Cervantes
Pedro Peña Santoyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excalibur Pharmaceuticals Inc
Original Assignee
GRUPO MEDIFARMA SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRUPO MEDIFARMA SA de CV filed Critical GRUPO MEDIFARMA SA de CV
Assigned to GRUPO MEDIFARMA S.A. DE C.V. reassignment GRUPO MEDIFARMA S.A. DE C.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAGAÑA CASTRO, José Agustín Rogelio, PEÑA SANTOYO, Pedro, VÁZQUEZ CERVANTES, Laura
Publication of US20150231098A1 publication Critical patent/US20150231098A1/en
Assigned to GRUPO MEDIFARMA S.A. DE C.V reassignment GRUPO MEDIFARMA S.A. DE C.V CORRECTIVE ASSIGNMENT TO CORRECT THE ATTORNEY FAX AND PHONE NUMBERS PREVIOUSLY RECORDED AT REEL: 035097 FRAME: 0153. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: MAGAÑA CASTRO, José Agustín Rogelio, PEÑA SANTOYO, Pedro, VÁZQUEZ CERVANTES, Laura
Assigned to EXCALIBUR PHARMACEUTICALS, INC. reassignment EXCALIBUR PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRUPO MEDIFARMA S.A. DE C.V.
Assigned to EXCALIBUR PHARMACEUTICALS, INC. reassignment EXCALIBUR PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRUPO MEDIFARMA S.A. DE C.V.
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/008Preparations for oily skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a hydrosoluble pharmaceutical antiseptic, antiseborrheic and exfoliating composition
  • a hydrosoluble pharmaceutical antiseptic, antiseborrheic and exfoliating composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid) to remove bacteria affecting the skin, besides said composition provides a deep cleansing because it reduces the epidermal cohesion and facilitates the cellular replacement, preventing or removing the occurrence of several forms of alterations in the skin.
  • DDMO diallyl disulphide modified oxide
  • glycolic acid alpha hydroxyethanoic acid
  • the skin has a microbial flora, which can be affected by changes in normal conditions of the skin, more likely acne is the most frequency of these alterations, due to the multiple factors altering it and producing a balance loss of the microbial flora.
  • Acne is an inflammatory illness of the pilosebaceous follicles, associated to the keratinization and seborrhea alterations; characterized by the formation of skin wounds such as: blackheads, papulae, pustules, cysts or abscesses, which frequently leave residual scars.
  • the cause of acne is precisely unknown, due to the fact that a great amount of factors jointly intervene, however, among them it is worth mentioning the genetic factor, which in combination with the endocrinal, inflammatory and infectious factors, are somehow the cause of the polymorphic characteristic of acne.
  • the genetic predisposition is not mediated by one simple Mendelian character, but it is caused by an intermediary of a polygenic mechanism, which originates special receptiveness of the pilosebaceous follicle, in order to more intensely responds to androgens, different from how healthy people respond.
  • the sebaceous gland has direct and indirect antibacterial activities.
  • the sebaceous gland produces antibacterial peptides and proinflammatory cytokines that are induced in sebocytes due to the presence of bacteria.
  • Androgens are hormones synthesized in testicles, ovaries and suprarenal cortex.
  • hypophysis starts to secrete greater amounts of luteinizing hormones (HL) and follicle-stimulating hormones (FSH), which together are responsible for the increase in testicular growth, spermatogenesis, and steroidogenesis.
  • HL luteinizing hormones
  • FSH follicle-stimulating hormones
  • Testosterone acts upon sebaceous glands, increasing their size and fat synthesis; in women the mechanism is similar.
  • biopsies to the face skin in patients with acne it has been proven that during puberty the sebaceous glands are bigger and foliated.
  • Propionibacterium acnes Some time ago it was believed that acne was just an infectious process caused by the bacteria “ Acne bacillus ”, now called Propionibacterium acnes .
  • the cutaneous flora is essentially a triad lead by the Propionibacterium acnes , in addition to Staphylococcus epidermis and yeast, which can be Pityrosporum ovale or Pityrosporum orbiculare.
  • Propionibacterium acnes and Staphylococcus epidermidis are produces of a lipase that hydrolyzes triglycerides from fat in fat-free acids, which are potent irritants from the follicular channel, when applied on the skin or intradermally injected, they cause inflammation and blackheads.
  • Propionibacterium acnes alternately activates the complement system, this fact has allowed to propose that this infectious mechanism could also play an important role in the production of acne inflammatory injuries.
  • the recently synthesized fat contains triglycerides, squalene and wax esters, and it is known that Propionibacterium acnes through a lipase hydrolyzes triglycerides from this sebaceous material, thus converting them into fat free acids, which in addition to other irritant substances as squalene and oleic acid cause inflammation of the follicular channel, which responds to the inflammation with hyperkeratosis.
  • the resulting corneous material fall in the light of the follicle, which in addition to the fat excess forms wax substituting and easing the follicle walls, accordingly by not being able to excrete material, it inflames more, causing the first and most important acne elemental injury: the blackhead, causing dilation of the follicular hole due to the pressure the wax applies when trying to be expelled.
  • MMP's matrix metaloproteinases
  • This product of P. acnes induces the synthesis of the alpha tumor necrosis factor ( ⁇ -TNF) and interleucine 1-beta (IL1- ⁇ ) in said cellular lines. It was also shown that the induction of cytokines by P. acnes would happen through the activation of the “TOLL-LIKE-2” Receptor (TLR-2) shooting inflammatory responses.
  • TLR-2 TOLL-LIKE-2 Receptor
  • the diallyl disulphide oxide (DDO) is also known as allicin, is the product from the conversion of allina, which is found in garlic ( Allium sativum ), by means of allinase enzyme catalysis. It is a sulfurated compound containing diverse pharmacological activities of interest.
  • the DDO is not naturally found in garlic, but when the bulb fractures, it is cut or grinded, liberates allina, which when contacting the allinase enzyme creates the active principle. Allina is found in amounts varying from 0.22-0.24% by weight of garlic and is an amino acid that is it not a structural part of any protein and it is not biochemically essential for human nutrition.
  • DDO has in vitro activity against Candida albicans , some Trichomonas, Staphylococcus aureus; Escherichia coli, Salmonella typhi, S. paratyphi, Shigella dysenterica and Vibro cholera species.
  • the diallyl disulphide modified oxide [DDMO] is the chemical compound called [1,2-alpha-glucodiallyl-disulphide oxide, 2-propen+chloride-6 alkyl (benzyl, methyl, octyl ammonium-hydroxymethylamine); whose structural formula is represented as follows:
  • hydroxyethanoic acid is also called glycolic acid, which is an acid of small molecular chain having the ability to penetrate the skin faster that deeper layers. It is shown colorless, odorless, and hygroscopic crystalline solid that is highly water-soluble and in related solvents.
  • This acid is largely used in dermatologic treatments, there are studies demonstrating its efficacy, through methods such as computerized morphometry on corneal layers from biopsies. Normally it is employed in association with other dermatologic products supporting the cellular reconstruction of the skin, thus becoming the so-called “soft-peeling” base.
  • the treatment action with hydroxyethanoic acid is to decrease the corneal layer thickness of the skin and to increase the malpighian layer thickness; the fractions of areas occupied by collagen in dermal layers significantly increases, thereby there is an improvement in the appearance of atrophic scars from acne and in the treatment of human skin wrinkles. It is also an excellent exfoliator, thus helping to significantly prevent and combat acne in any body part.
  • the glycolic acid also lets other components to more easily penetrate the skin, thus it is advisable to also use the so-called complete treatments.
  • the hydroxic acid also has seboregulating properties by increasing the peeling of cells and thus avoiding blockage of the sebaceous glands and the formation of blackheads and other acne injuries.
  • a first object of the present invention is to provide antimicrobial, exfoliating and seboregulating pharmaceutical hydrosoluble compositions comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha-hydroxyethanoic acid (glycolic acid) to remove or prevent acne.
  • DDMO diallyl disulphide modified oxide
  • glycolic acid alpha-hydroxyethanoic acid
  • a second object is to obtain compositions comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha-hydroxyethanoic acid (glycolic acid), antimicrobials/antiseptics, stable, biodegradable and non-poisonous topical application exfoliants and seboregulators having as an antimicrobial function a wide action spectrum, not just against gram negative and gram positive microorganisms, but against fungus as well.
  • DDMO diallyl disulphide modified oxide
  • glycolic acid alpha-hydroxyethanoic acid
  • the present invention is related to antimicrobial, exfoliating and seboregulating pharmaceutical hydrosoluble compositions comprising from 0.001 to 10% p/w of the DDMO composition, from 1 to 12% p/w of alpha-hydroxyethanoic acid (glycolic acid), from 0.3 to 24% p/w of one or more surfactants, from 0.3 to 10% p/w of a moisturizing agent, from 0.2 to 10% p/w of an aromatizing agent and from 40 to 70% p/w of the composition of an aqueous solvent.
  • the object compositions of the present invention comprise one or more surfactants selected from the group consisting of lineal alkyl benzene sulfates and ionic alkyl sulfates.
  • the surfactants useful in the object compositions of the present invention preferably are sodium lauryl sulfate and sodium lauryl ether sulfate.
  • the ionic alkyl surfactants such as sodium lauryl sulfate that is an anionic surfactant, are used in a variety of pharmaceutical non-parenteral formulations.
  • the sodium lauryl sulfate is a detergent and moisturizing agent, effective in acid, alkaline solutions and in hard water. It is used in medicated shampoos, such as skin cleaner and dentifrices, it is usually known as “Cosmetic Detergent”, makes foam and bubbles and is good for removing grease and oil from skin and hair.
  • the sodium lauryl ether sulfate is the most frequently used active anion surfactant in the manufacture of cleaning, scrubbing and domestic washing products, as well as cosmetic and personal hygiene products.
  • the sodium lauryl ether sulfate does not irritate the skin and if from natural origin; additionally it is valued for its easy degradations and properties in relation to the formation of foam.
  • the sodium lauryl ether sulfate is mainly used in the production process of shampoos, liquid soaps, face skin creams, dental creams, etc.
  • the surfactant preferably used in the present invention are sodium lauryl sulfate, sodium lauryl ether sulfate and ammonium lauryl sulfate.
  • the moisturizing agent is selected from the group consisting of ethylene glycol, propylene glycol, glycerin, sorbitol, low molecular weight polyethylenes, polyoxyethylated glycerols, polyoxyethylated sugars, for example, MEA acetamide, and the like.
  • the moisturizing agent is glycerin, which has a wide variety of applications, such as emulsifier, softening agent, laminate, stabilizing and moisturizing agent for baking shop, ice-cream shop and cigar store, in body lotions, mouthwashes, as protecting means for freezing of red blood cells, sperm, corneas and other tissues in printing inks, paint resins; antifreezing mixtures; and as raw material for nitroglycerin. It is used in the manufacture of countless prepared pharmaceuticals and cosmetics; for example in soaps, glycerin increases its detergency, whitening and softening of the skin. Between 8-15% of glycerin can be found in the compositions of these soaps.
  • moisturizing agents useful in the compositions claimed in the present invention comprise among others:
  • An aqueous solvent which is selected from water and water-hydrosoluble alcohol mixtures.
  • compositions contribute to eliminate bacteria causing acne providing a deep and delicate cleansing of the skin; even in oily skins, improving the habitual look and freshness.
  • it provides an exfoliating action, reducing the epidermal adhesion and facilitating the cellular change, eliminating dead skin cells.
  • they remove the grease and oil excess present in the acne skin, thus preventing obstruction of the pores, removing comedonal block and avoiding formation of new blackheads and pustules.
  • the antimicrobial action mechanism of DDMO probably comprises the following:
  • ROS oxide-reduction creating free radicals
  • An antimicrobial and antiseptic hydrosoluble composition was prepared containing:
  • a second composition was prepared containing the following elements:
  • a third example of the object compositions of the present invention is shown, thus proving that the embodiments of the same only limit to preserving the homogeneous distribution aspects of all components.

Abstract

The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a hydrosoluble pharmaceutical antiseptic, antiseborrheic and exfoliating composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid) to remove bacteria affecting the skin, besides said composition provides a deep cleansing because it reduces the epidermal cohesion and facilitates the cellular replacement, preventing or removing the occurrence of several forms of alterations in the skin.
  • BACKGROUND OF THE INVENTION
  • The skin has a microbial flora, which can be affected by changes in normal conditions of the skin, more likely acne is the most frequency of these alterations, due to the multiple factors altering it and producing a balance loss of the microbial flora.
  • Acne is an inflammatory illness of the pilosebaceous follicles, associated to the keratinization and seborrhea alterations; characterized by the formation of skin wounds such as: blackheads, papulae, pustules, cysts or abscesses, which frequently leave residual scars.
  • Acne is undoubtedly the most frequent skin disease in the entire world; traditionally the three main factors considered to intervene in the appearance of acne were microbial infection, overproduction of fat and abnormal peeling of epidermal cells that finally cause an excess in the keratinization, but recent studies add as causing effects of acne genetic predisposition and inflammatory factor.
  • It is calculated that about 85% of the population between the ages of 11 and 30 suffer from acne; this represents only in Mexico an approximate total of 20 million people. The incidence curves show a maximum peak at 18 years old, from this point a gradual decrease is appreciated, which increases after 30 years of age; however, between 25 and 35% of adults over 35 years old go through occasional acne exacerbations.
  • The cause of acne is precisely unknown, due to the fact that a great amount of factors jointly intervene, however, among them it is worth mentioning the genetic factor, which in combination with the endocrinal, inflammatory and infectious factors, are somehow the cause of the polymorphic characteristic of acne.
  • There are 5 main primary pathogenic factors interacting in a complex manner to produce acne injuries.
      • 1. Genetic predisposition.
      • 2. Overproduction of fat by sebaceous glands.
      • 3. Alteration in the keratinization process with abnormal peeling of the sebaceous follicular epithelium (causing comedogenesis).
      • 4. Proliferation of Propionibacterium acnes.
      • 5. Release of inflammatory intermediaries on the skin, mainly alpha-TNF and alpha IL-1.
  • The genetic predisposition is not mediated by one simple Mendelian character, but it is caused by an intermediary of a polygenic mechanism, which originates special receptiveness of the pilosebaceous follicle, in order to more intensely responds to androgens, different from how healthy people respond.
  • Research made about the role of fat in acne has allowed to establishing that the sebaceous lipids are regulated by the peroxisome proliferator activated-receptors (PPAR) and by sterol transcription factors.
  • Other research of the sebaceous gland function has contributed to obtaining information about the main role these glands play in regulating skin functions. The sebaceous gland has direct and indirect antibacterial activities. Likewise, the sebaceous gland produces antibacterial peptides and proinflammatory cytokines that are induced in sebocytes due to the presence of bacteria.
  • Androgens are hormones synthesized in testicles, ovaries and suprarenal cortex. During puberty, through little known mechanisms, the hypophysis starts to secrete greater amounts of luteinizing hormones (HL) and follicle-stimulating hormones (FSH), which together are responsible for the increase in testicular growth, spermatogenesis, and steroidogenesis. Testosterone acts upon sebaceous glands, increasing their size and fat synthesis; in women the mechanism is similar. Through biopsies to the face skin in patients with acne, it has been proven that during puberty the sebaceous glands are bigger and foliated.
  • Some time ago it was believed that acne was just an infectious process caused by the bacteria “Acne bacillus”, now called Propionibacterium acnes. The cutaneous flora is essentially a triad lead by the Propionibacterium acnes, in addition to Staphylococcus epidermis and yeast, which can be Pityrosporum ovale or Pityrosporum orbiculare.
  • It is possible that the association between bacteria and the pathogenesis of the acne is reinforced by well-documented findings about clinical improvement in patients with acne treated with systemic antibiotics. The antibacterial therapy does not affect the P. orbiculare or P. ovale since they reside on the upper part of the acrofundibulum of the sebaceous follicle. The anaerobe P. acnes on the other hand seems to play a central role in the development of acne inflammation. The most important evidence might be the demonstration that therapy with antibiotics results in a significant suppression of P. acnes, which is accompanied in one reduction in the number of inflammatory injuries.
  • Propionibacterium acnes and Staphylococcus epidermidis are produces of a lipase that hydrolyzes triglycerides from fat in fat-free acids, which are potent irritants from the follicular channel, when applied on the skin or intradermally injected, they cause inflammation and blackheads.
  • It must also be noted that the Propionibacterium acnes alternately activates the complement system, this fact has allowed to propose that this infectious mechanism could also play an important role in the production of acne inflammatory injuries.
  • During puberty, and in response to the androgens produced in greater amounts in this stage, the sebaceous glands that were relatively inactive, increase in size and become more foliated, thus increasing the production of fat spilled on the outside; thereby the first sign of acne: seborrhea.
  • The recently synthesized fat contains triglycerides, squalene and wax esters, and it is known that Propionibacterium acnes through a lipase hydrolyzes triglycerides from this sebaceous material, thus converting them into fat free acids, which in addition to other irritant substances as squalene and oleic acid cause inflammation of the follicular channel, which responds to the inflammation with hyperkeratosis. The resulting corneous material fall in the light of the follicle, which in addition to the fat excess forms wax substituting and easing the follicle walls, accordingly by not being able to excrete material, it inflames more, causing the first and most important acne elemental injury: the blackhead, causing dilation of the follicular hole due to the pressure the wax applies when trying to be expelled.
  • In several studies, it was been studied in depth the role of the inflammatory mediators, as well as the interrelation of this factor with sebaceous lipids and matrix metaloproteinases (MMP's) in the physiology of acne.
  • One of the pioneer researches in this field was developed by Jeremy and co-workers in 2003, who researched the initial events of acne injuries and found that the immunological changes and inflammatory responses occurred before the hyperproliferation of keratinocytes, with a similar pattern to a type IV retarded hypersensitivity. An important fact is that the whole process starts by the exacerbated regulation of IL1-β having a proinflammatory action in response to the linoleic acid relative deficiency caused by the fat excess and by the disturbance of the barrier function inside the follicle. Vowels and co-workers proved in an in vitro study the presence of a P. acnes soluble factor that also induces the production of pro-inflammatory cytokines in cellular lines derived from human monocytes. This product of P. acnes induces the synthesis of the alpha tumor necrosis factor (α-TNF) and interleucine 1-beta (IL1-β) in said cellular lines. It was also shown that the induction of cytokines by P. acnes would happen through the activation of the “TOLL-LIKE-2” Receptor (TLR-2) shooting inflammatory responses.
  • Other recent studies have proved that this chain of events occurs in inflammatory injuries from patients with facial acne. It has been shown that the Propionibacterium acnes also induces type Toll receptors. This provides additional evidence that the inflammatory cytokines, which act through autocrine and paracrine mechanisms amplifying their corresponding receptors and amplifying the signaling way that activates the Activator Protein-1 (AP-1) that is a transcriptional factor.
  • In treating acne, the use of antimicrobials is a normal and habitual behavior among doctors, since there is clinically an improvement in patients with acne when using this type of products, this due to the strengthening factor of P. acnes in the fat metabolism that creates an irritant effect causing greater inflammation on the patient.
  • The diallyl disulphide oxide (DDO) is also known as allicin, is the product from the conversion of allina, which is found in garlic (Allium sativum), by means of allinase enzyme catalysis. It is a sulfurated compound containing diverse pharmacological activities of interest. The DDO is not naturally found in garlic, but when the bulb fractures, it is cut or grinded, liberates allina, which when contacting the allinase enzyme creates the active principle. Allina is found in amounts varying from 0.22-0.24% by weight of garlic and is an amino acid that is it not a structural part of any protein and it is not biochemically essential for human nutrition.
  • Since it is a not much stable compound, the DDO quickly loses its properties, on the other hand if garlic is heated over 60° C. it loses its properties. It has a strong oxidative power that could cause harm to intestinal cells.
  • It has been shown that DDO has in vitro activity against Candida albicans, some Trichomonas, Staphylococcus aureus; Escherichia coli, Salmonella typhi, S. paratyphi, Shigella dysenterica and Vibro cholera species.
  • The structural formula of allicin is shown below:
  • Figure US20150231098A1-20150820-C00001
  • In 1944 Cavallito and his co-workers were able to isolate and identify the active compound from the extracts of Allium sativum which they called allicin and in 1947 they were able to synthesize the diallyl disulphide oxide (allicin), but unfortunately they were not able to make the molecule thereof stable, since it kept losing its efficacy in a very short period of time. A group of Mexican researchers from 2000 and 2005 were able to stabilize the diallyl disulphide oxide, adding a co-factor, compound called diallyl disulphide modified oxide [DDMO], which is much more stable than allicin and it seems to maintain its properties.
  • The diallyl disulphide modified oxide [DDMO], is the chemical compound called [1,2-alpha-glucodiallyl-disulphide oxide, 2-propen+chloride-6 alkyl (benzyl, methyl, octyl ammonium-hydroxymethylamine); whose structural formula is represented as follows:
  • Figure US20150231098A1-20150820-C00002
  • In diverse studies it has been shown the activity of allicin, however its little stability has been a limitation in its possible therapeutic applications. Accordingly, it is clear that the application of the stability properties of compound DDMO, will allow the therapeutic application based on its antibacterial and anti-septic properties among others from allicin.
  • On the other hand, hydroxyethanoic acid (HAA), is also called glycolic acid, which is an acid of small molecular chain having the ability to penetrate the skin faster that deeper layers. It is shown colorless, odorless, and hygroscopic crystalline solid that is highly water-soluble and in related solvents. This acid is largely used in dermatologic treatments, there are studies demonstrating its efficacy, through methods such as computerized morphometry on corneal layers from biopsies. Normally it is employed in association with other dermatologic products supporting the cellular reconstruction of the skin, thus becoming the so-called “soft-peeling” base. The treatment action with hydroxyethanoic acid is to decrease the corneal layer thickness of the skin and to increase the malpighian layer thickness; the fractions of areas occupied by collagen in dermal layers significantly increases, thereby there is an improvement in the appearance of atrophic scars from acne and in the treatment of human skin wrinkles. It is also an excellent exfoliator, thus helping to significantly prevent and combat acne in any body part. The glycolic acid also lets other components to more easily penetrate the skin, thus it is advisable to also use the so-called complete treatments. The hydroxic acid also has seboregulating properties by increasing the peeling of cells and thus avoiding blockage of the sebaceous glands and the formation of blackheads and other acne injuries.
  • OBJECT OF THE INVENTION
  • A first object of the present invention is to provide antimicrobial, exfoliating and seboregulating pharmaceutical hydrosoluble compositions comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha-hydroxyethanoic acid (glycolic acid) to remove or prevent acne.
  • A second object is to obtain compositions comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha-hydroxyethanoic acid (glycolic acid), antimicrobials/antiseptics, stable, biodegradable and non-poisonous topical application exfoliants and seboregulators having as an antimicrobial function a wide action spectrum, not just against gram negative and gram positive microorganisms, but against fungus as well.
  • The previous objects are representative, but they shall not be considered as limitative to the present invention, wherein it is further shown its treatment methods, applications and/or pharmaceutical uses in the preparation of medicaments to remove, reduce or prevent microbial injuries of the skin, including acne.
  • DESCRIPTION OF THE INVENTION
  • The present invention is related to antimicrobial, exfoliating and seboregulating pharmaceutical hydrosoluble compositions comprising from 0.001 to 10% p/w of the DDMO composition, from 1 to 12% p/w of alpha-hydroxyethanoic acid (glycolic acid), from 0.3 to 24% p/w of one or more surfactants, from 0.3 to 10% p/w of a moisturizing agent, from 0.2 to 10% p/w of an aromatizing agent and from 40 to 70% p/w of the composition of an aqueous solvent. Particularly, the object compositions of the present invention comprise one or more surfactants selected from the group consisting of lineal alkyl benzene sulfates and ionic alkyl sulfates.
  • The surfactants useful in the object compositions of the present invention preferably are sodium lauryl sulfate and sodium lauryl ether sulfate.
  • The ionic alkyl surfactants, such as sodium lauryl sulfate that is an anionic surfactant, are used in a variety of pharmaceutical non-parenteral formulations. For example, the sodium lauryl sulfate is a detergent and moisturizing agent, effective in acid, alkaline solutions and in hard water. It is used in medicated shampoos, such as skin cleaner and dentifrices, it is usually known as “Cosmetic Detergent”, makes foam and bubbles and is good for removing grease and oil from skin and hair.
  • Likewise, the sodium lauryl ether sulfate is the most frequently used active anion surfactant in the manufacture of cleaning, scrubbing and domestic washing products, as well as cosmetic and personal hygiene products. The sodium lauryl ether sulfate does not irritate the skin and if from natural origin; additionally it is valued for its easy degradations and properties in relation to the formation of foam. The sodium lauryl ether sulfate is mainly used in the production process of shampoos, liquid soaps, face skin creams, dental creams, etc.
  • The surfactant preferably used in the present invention are sodium lauryl sulfate, sodium lauryl ether sulfate and ammonium lauryl sulfate.
  • The moisturizing agent is selected from the group consisting of ethylene glycol, propylene glycol, glycerin, sorbitol, low molecular weight polyethylenes, polyoxyethylated glycerols, polyoxyethylated sugars, for example, MEA acetamide, and the like. Preferably, the moisturizing agent is glycerin, which has a wide variety of applications, such as emulsifier, softening agent, laminate, stabilizing and moisturizing agent for baking shop, ice-cream shop and cigar store, in body lotions, mouthwashes, as protecting means for freezing of red blood cells, sperm, corneas and other tissues in printing inks, paint resins; antifreezing mixtures; and as raw material for nitroglycerin. It is used in the manufacture of countless prepared pharmaceuticals and cosmetics; for example in soaps, glycerin increases its detergency, whitening and softening of the skin. Between 8-15% of glycerin can be found in the compositions of these soaps.
  • Other moisturizing agents useful in the compositions claimed in the present invention comprise among others:
  • A aromatizing agent selected from any of the available ones for the pharmaceutical and food industry.
  • An aqueous solvent, which is selected from water and water-hydrosoluble alcohol mixtures.
  • With these elements, it is possible to extract a wide range of antimicrobial, exfoliating and seboregulating pharmaceutical compositions containing DDMO and alpha-hydroxyethanoic acid (glycolic acid), useful in treating and preventing skin microbial injuries.
  • Said compositions contribute to eliminate bacteria causing acne providing a deep and delicate cleansing of the skin; even in oily skins, improving the habitual look and freshness. In addition to its antimicrobial action, it provides an exfoliating action, reducing the epidermal adhesion and facilitating the cellular change, eliminating dead skin cells. Also, they remove the grease and oil excess present in the acne skin, thus preventing obstruction of the pores, removing comedonal block and avoiding formation of new blackheads and pustules.
  • The information obtained from microbiologic tests (antimicrobial challenge) of the DDMO and alpha-hydroxyethanoic acid (glycolic acid) against several bacteria, has proven the great antibacterial capacity of the formulations, insisting on the results against Propionibacterium acnes, thus proving the removal of said bacteria in a matter of seconds.
  • The antimicrobial action mechanism of DDMO, probably comprises the following:
  • 1. Alteration of the microbial mechanism, inhibiting the action of 11 essential enzymes for cellular respiration of the microorganism. This inhibiting effect is created from the chemical reaction of the sulfhydryl radicals of DDMO about the molecular structure of the sulfurated enzymes of the microorganism, whether by inserting sulfurated radicals or by modifying the enzyme protein, thus causing death of the microorganism.
  • 2. Through reactions of oxide-reduction creating free radicals (ROS), which by oxidative stress break the cellular wall of the microorganism, by acting “sequestering” oxygen serving as link between the NAG (n-Acetyl glucosamine acid) and NAM (N-Acetyl muramic acid) chains, thus weakening the microorganism wall causing rupture and thereby death of the microorganism.
  • 3. Inhibition of the genetic transcription process and unfolding of the microorganism proteins, through the activation of the polymerase ARN enzyme, which is an enzyme, since being of sulfurated composition, is vulnerable to chemical attack from the DDMO.
  • 4. Alteration of the metal metabolism in the microorganism, also causing metabolic alterations therein.
  • The foregoing has been inferred from studies made with allicin, reported by Yosuda et al, Biosci. Biotechnol. Biochem., 63(3) 591-594, 1999; Feldherg et al, Antimicrobial Agents and Chemotherapy, December 1988, 1763-1768; Munchberg et al, Org. Biomol. Chem., 2007, 5, 1505-1518; among others. Considering that DDMO is an stabilized allicin molecule owing its antimicrobial action precisely to this allicin fragment, whose activity is preserved without alteration as shown in the microbiological tests.
  • The microbiological challenges were made with collection microorganisms, universally required to test the product effectiveness. The results proved that in 30 seconds of contact with the composition from Example 1, 100.00% was removed from the challenged microorganisms, including Candida albicans. The results from the study are shown in Table 1.
  • TABLE 1
    Studies from microbial challenge
    Test Microorganism Contact Time 30 Sec
    Escherichia coli 100%
    ATCC 10536
    Pseudomona aerugiosa 100%
    ATCC 9027
    Klebsiella pneumoniae 100%
    ATCC 10031
    Proteus vulgaris 100%
    ATCC 6380
    Staphylococcus aureus 100%
    ATCC 6538
    Staphylococcus epidermis 100%
    ATCC 12228
    Candida albicans 100%
    ATCC 1031
  • Additionally, challenge tests were made against Propionilbacterium acnes, anaerobic bacteria previously referred to as one of the main causes of infection caused by acne, thus obtaining excellent results, such as it is shown below in Table 2.
  • TABLE 2
    Contact Time Eradication
    Test Microorganism 30 seconds 60 seconds
    Propionibacterium acnes 98% 99.999%
  • The results of these microbial challenges are more encouraging that those reported by Fujisawa et al, Biosci. Biotechnol. Biochem. 73 (9) 1984-1955, 2009; Tsao et al Journal of Medical Microbiology (2007) 56, 803-808. And they confirm the review by Ankri and Mirelman, Microbes and Infection, 2, 1999, 125-129 and by Domingo and Lopez-Brea in Rev. Esp. Quimioterap. December 2003, Vol. 16 (no. 4) 285-293 (2003).
  • Example 1
  • An antimicrobial and antiseptic hydrosoluble composition was prepared containing:
  • Component Kg
    a-hydroxyethanoic acid 57.1
    DDMO 4
    Sodium lauryl sulfate 50
    Sodium lauryl ether sulfate 50
    Glycerin 2.5
    Blue fragrance 3
    Purified water 333.4
  • Example 2
  • A second composition was prepared containing the following elements:
  • Component Kg
    a-hydroxyethanoic acid 58
    DDMO 5
    Sodium lauryl sulfate 40
    Sodium lauryl ether sulfate 60
    Ethylene glycol 2.5
    Floral fragrance 3
    Purified water 331.5
  • Example 3
  • A third example of the object compositions of the present invention is shown, thus proving that the embodiments of the same only limit to preserving the homogeneous distribution aspects of all components.
  • Component Kg
    a-hydroxyethanoic acid 57.1
    DDMO 4
    Sodium lauryl ether sulfate 100
    Sorbitol 2
    Blue fragrance 3
    Purified water-ethanol (9:1) 333.9
  • Clinical Trials:
  • A clinical trial was made applying the product of the present invention (example 1) during 28 days to 20 patients with moderate acne, according to the classification shown in Table 3 below.
  • TABLE 3
    Grade* Description
    0 Clean skin with no inflammatory or non-inflammatory wounds
    1 Almost clean; Little non-inflammatory wounds and no more tan
    two inflammatory wounds
    2 Middle severity; greater than grade 1; some non-inflammatory
    wounds, few inflammatory wounds (only papules/pustules;
    no nodular wounds)
    3 Moderate severity; greater than grade 2; many non-inflammatory
    wounds and several can be inflammatory, but no more than two
    nodular wounds.
    4 Severe; greater than grade 3; many inflammatory and
    non-inflammatory wounds; and some nodular wounds.
    *FDA's classification scale of acne

    The number of wounds from each patient was counted by two different observers before treatment and during the same each week. The resulting data is shown in table 4, wherein it can be seen that the treatment gave an average reduction close to 35% of the active wounds after 28 days of treatment.
  • TABLE 4
    No. Of Inflammatory Wounds
    Number Day 0 7 days 14 days 21 days 28 days
    1 58 +/− 5 51 +/− 5 45 +/− 4 41 +/− 3 37 +/− 3
  • On the other hand, patients were asked to assess the presence of grease, through the use of drying paper, measuring the number of sheets needed in order not to get the forehead stained 2 hours after cleaning with the product, thus discovering that patients considerably reduced the number of drying sheets used for cleaning the grease, the results are shown in Table 5.
  • TABLE 5
    No. Of Sheets
    Day 0 7 days 14 days 21 days 28 days
    5 +/− 2 2 +/− 2 1 +/− 2 1 +/− 1 1 +/− 1
  • The results show that the antiseptic, antiseborrheic and exfoliating composition of the present invention is able to achieve an effective treatment for seborrhea and acne. These results show that the treatment for these disorders according to the present invention is clearly better than the pre-existing methods.

Claims (9)

1. An antimicrobial, exfoliating and seboregulating pharmaceutical hydrosoluble composition to remove or prevent skin microbial injuries, including acne, characterized in that it comprises from 0.001 to 10% p/w of the DDMO composition, from 1 to 12% p/w of alpha hydroxyethanoic acid (glycolic acid), from 0.3 to 24% p/w of one or more surfactants, from 0.3 to 10% p/w of a moisturizing agent, from 0.2 to 10% p/w of an aromatizing agent and from 40 to 70% p/w of the composition of an aqueous solvent.
2. The composition according to claim 1, characterized in that the surfactants are selected from the group consisting of lineal alkylbenzensulfates and ionic alkyl sulfates.
3. The composition according to claims 1 and 2, characterized in that the surfactants preferably are sodium lauryl sulfate, sodium lauryl ether sulfate and ammonium lauryl sulfate.
4. The composition according to claim 1, characterized in that the moisturizing agent is selected from the group consisting of ethylene glycol, propylene glycol, glycerin, sorbitol, low molecular weight polyethylenes, polyoxyethylated glycerols, polyoxyethylated sugars.
5. The composition according to claim 1, characterized in that the aromatizing agent is selected from those available for the pharmaceutical and food industry.
6. The composition according to claim 1, characterized in that the solvent is selected from water and water-hydrosoluble alcohol mixtures.
7. The use of the composition according to claim 1, for making a medicine to remove, reduce or prevent acne.
8. The use of the composition according to claims 1 to 6, for making a medicine to remove bacteria causing acne, providing deep and delicate cleansing to normal and oily skin, providing exfoliating action, eliminating death cells from the skin, removing grease and fat excess present in skin with acne, avoiding the obstruction of pores, removing the comedonal block and avoiding the formation of new blackheads and pustules.
9. A method for removing, reducing and preventing acne, characterized in that it comprises to administer the skin of an individual in need of said treatment an antimicrobial and antiseptic pharmaceutical hydrosoluble composition according to any of claims 1 to 6.
US14/421,616 2012-08-23 2013-08-22 Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne Abandoned US20150231098A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2012/009806 2012-08-23
MX2012009806A MX356551B (en) 2012-08-23 2012-08-23 Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
PCT/MX2013/000099 WO2014030992A2 (en) 2012-08-23 2013-08-22 Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2013/000099 A-371-Of-International WO2014030992A2 (en) 2012-08-23 2013-08-22 Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/008,210 Continuation US20180353448A1 (en) 2012-08-23 2018-06-14 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne

Publications (1)

Publication Number Publication Date
US20150231098A1 true US20150231098A1 (en) 2015-08-20

Family

ID=49230828

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/421,616 Abandoned US20150231098A1 (en) 2012-08-23 2013-08-22 Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne
US16/008,210 Abandoned US20180353448A1 (en) 2012-08-23 2018-06-14 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US16/371,670 Active US10792258B2 (en) 2012-08-23 2019-04-01 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US17/063,458 Abandoned US20210093593A1 (en) 2012-08-23 2020-10-05 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US17/855,072 Pending US20230165819A1 (en) 2012-08-23 2022-06-30 Antiseptic, antiseborrheic, exfoliating composition to remove or prevent acne

Family Applications After (4)

Application Number Title Priority Date Filing Date
US16/008,210 Abandoned US20180353448A1 (en) 2012-08-23 2018-06-14 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US16/371,670 Active US10792258B2 (en) 2012-08-23 2019-04-01 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US17/063,458 Abandoned US20210093593A1 (en) 2012-08-23 2020-10-05 Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US17/855,072 Pending US20230165819A1 (en) 2012-08-23 2022-06-30 Antiseptic, antiseborrheic, exfoliating composition to remove or prevent acne

Country Status (7)

Country Link
US (5) US20150231098A1 (en)
AR (1) AR092199A1 (en)
CA (1) CA2882392C (en)
MX (1) MX356551B (en)
TW (1) TW201416071A (en)
UY (1) UY34985A (en)
WO (1) WO2014030992A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9949959B2 (en) 2012-03-28 2018-04-24 Cell Therapy and Technology S.A. DE C.V. Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US10376500B2 (en) 2007-08-14 2019-08-13 Cell Therapy and Technology S.A. DE C.V. Gel containing pirfenidone
US10792258B2 (en) 2012-08-23 2020-10-06 Excalibur Pharmaceuticals, Inc. Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US11040030B2 (en) 2011-07-19 2021-06-22 Excalibur Pharmaceuticals, Inc. Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form
US11576905B2 (en) 2017-08-15 2023-02-14 Excalibur Pharmaceuticals, Inc. Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111763630A (en) * 2019-03-27 2020-10-13 深圳微健康基因科技有限公司 Staphylococcus epidermidis and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235946A1 (en) * 2003-05-23 2004-11-25 Ott David M. Organosulphur prodrugs for the prevention and treatment of injectious diseases and pathologenic immune system response
US20060051339A1 (en) * 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same
US7109246B1 (en) * 1998-05-22 2006-09-19 Hewlett Healthcare Ltd Pharmaceutical compositions comprising an amphoteric surfactant an alkoxylated cetyl alcohol and a polar drug

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105782A (en) * 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
CZ293747B6 (en) 1995-12-21 2004-07-14 Pfizer Inc. Aqueous pharmaceutical solution suitable for injection into a host and use thereof
US5958420A (en) 1997-03-13 1999-09-28 Nortrade Medical, Inc. Treatment of burns, cuts, and abrasions of the skin
US6365131B1 (en) 1997-10-31 2002-04-02 J. B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic
DE69810518D1 (en) 1998-09-18 2003-02-06 Mepha Ag Aesch TOPICALLY ADMINISTRABLE ALKYL, PHENYL PYRIDONE MEDICINAL PRODUCTS
IN191090B (en) 2000-08-29 2003-09-20 Ranbanx Lab Ltd
EP1356816B1 (en) 2001-01-29 2009-12-23 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2004073713A1 (en) 2003-02-21 2004-09-02 Shionogi & Co., Ltd. Pirfenidone gel preparation
US20060115503A1 (en) * 2004-11-30 2006-06-01 Goyal Muna C Composition, system and method for treatment of skin
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
JP2010520194A (en) * 2007-03-02 2010-06-10 ミロン、タリア Mercaptopurine derivatives as anticancer agents
EP2170828B1 (en) 2007-06-20 2012-11-21 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
MX2007009796A (en) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel containing pirfenidone.
CN101972236A (en) 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 Sustained release preparation containing pirfenidone
US9241921B2 (en) * 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
MX2011007675A (en) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Process for manufacturing a pharmaceutical composition in a sustained-release tablet form containing pirfenidone and the application thereof in the regression of chronic renal failure, breast capsular contracture and liver fibrosis in humans.
MX346763B (en) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Semi-solid topical composition which contains pirfenidone and modified diallyl disulphide oxide (m-ddo) for eliminating or preventing acne.
MX356551B (en) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Antiseptic, antiseborrheic, exfoliating composition for getting rid of or preventing acne.
MX352342B (en) 2013-07-12 2017-11-22 Moleculas Naturales S A De C V Star Process for the manufacture of improved benzethonium chloride-diallyl disulphide oxide modified complex, the obtained complex and uses thereof.
MX364040B (en) 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash).

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109246B1 (en) * 1998-05-22 2006-09-19 Hewlett Healthcare Ltd Pharmaceutical compositions comprising an amphoteric surfactant an alkoxylated cetyl alcohol and a polar drug
US20040235946A1 (en) * 2003-05-23 2004-11-25 Ott David M. Organosulphur prodrugs for the prevention and treatment of injectious diseases and pathologenic immune system response
US20060051339A1 (en) * 2004-09-08 2006-03-09 Sivak Hannah N Composition for treatment of oily skin and acne prevention and methods of making and using same

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376500B2 (en) 2007-08-14 2019-08-13 Cell Therapy and Technology S.A. DE C.V. Gel containing pirfenidone
US11083719B2 (en) 2007-08-14 2021-08-10 Excalibur Pharmaceuticals, Inc. Gel containing Pirfenidone
US11779574B2 (en) 2007-08-14 2023-10-10 Excalibur Pharmaceuticals, Inc. Gel containing pirfenidone
US11040030B2 (en) 2011-07-19 2021-06-22 Excalibur Pharmaceuticals, Inc. Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form
US11052074B2 (en) 2011-07-19 2021-07-06 Excalibur Pharmaceuticals, Inc. Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis
US9949959B2 (en) 2012-03-28 2018-04-24 Cell Therapy and Technology S.A. DE C.V. Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US11013727B2 (en) 2012-03-28 2021-05-25 Excalibur Pharmaceuticals, Inc. Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US11766426B2 (en) 2012-03-28 2023-09-26 Excalibur Pharmaceuticals, Inc. Semi-solid topical composition containing pirfenidone and modified diallyl disulfide oxide (M-DDO) for eliminating or preventing acne
US10792258B2 (en) 2012-08-23 2020-10-06 Excalibur Pharmaceuticals, Inc. Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US11576905B2 (en) 2017-08-15 2023-02-14 Excalibur Pharmaceuticals, Inc. Topical semisolid composition containing an antimicrobial agent and pirfenidone for the treatment of chronic skin damage

Also Published As

Publication number Publication date
UY34985A (en) 2014-02-28
CA2882392A1 (en) 2014-02-27
AR092199A1 (en) 2015-04-08
CA2882392C (en) 2021-10-12
US20190290606A1 (en) 2019-09-26
WO2014030992A2 (en) 2014-02-27
MX356551B (en) 2018-06-04
MX2012009806A (en) 2014-02-24
WO2014030992A3 (en) 2014-10-23
TW201416071A (en) 2014-05-01
US20180353448A1 (en) 2018-12-13
US20230165819A1 (en) 2023-06-01
US20210093593A1 (en) 2021-04-01
US10792258B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
US10792258B2 (en) Antiseptic, antiseborrheic and exfoliating composition to remove or prevent acne
US20200222358A1 (en) Topical dermatologic acne treatment cream composition and method of manufacture
WO2008140200A1 (en) External compositions for the skin
WO2004028520A1 (en) Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
WO2014131191A1 (en) A composition containing honokiol and/or magnolol and uses thereof
KR101253374B1 (en) Cosmetic composition for controlling anti-acne and anti-comedo
KR20090038648A (en) A composition using the cosmetic containing chamaecyparis obtusa oil for a pimpled skin
US20140287064A1 (en) Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument
EP3378475B1 (en) Composition and kit for the use in the prevention of recurrent onychomycosis
KR20210029359A (en) Cosmetic composition for improving acne
KR20170116334A (en) A cosmetic composition for manufacturing by the using of propolis, and the cosmetic manufactured by the composition
CA2878633C (en) Use of zinc coceth sulfate as an antibacterial agent against propionibacterium acnes
AU2018382466A1 (en) Propanediol monoacetate mononitrate
FR3034667A1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION AGAINST ACNE
JP3658626B2 (en) Cosmetics and quasi drugs
WO2016033899A1 (en) Dandruff removing composition for adjusting scalp oil balance
KR102200874B1 (en) Composition for improving skin condition comprising chitosan as a effective ingredient and method for preparing the same
KR102115668B1 (en) Cosmetic composition having anti-acne activity comprising probiotics fermentation product
EP3638219B1 (en) Composition comprising terpinene-4-ol for the treatment of demodicosis
KR20000065305A (en) Skin care composition containing stabilized retinol, phytosphingosine, and Castaneae crenata extracts
KR20150116504A (en) A cosmetics composition containing tea tree and solt
KR20040056079A (en) Cosmetic composition for preventing and therapeutic for a pimple
US11969405B2 (en) Method of treatment of topical dermatologic acne using a cream composition and method of manufacture
CN113413331B (en) Acne-removing composition and preparation and application thereof
US20160184220A1 (en) Method for the Prevention and Treatment of Acne

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUPO MEDIFARMA S.A. DE C.V., MEXICO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAGANA CASTRO, JOSE AGUSTIN ROGELIO;VAZQUEZ CERVANTES, LAURA;PENA SANTOYO, PEDRO;REEL/FRAME:035097/0153

Effective date: 20150224

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: GRUPO MEDIFARMA S.A. DE C.V, MEXICO

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ATTORNEY FAX AND PHONE NUMBERS PREVIOUSLY RECORDED AT REEL: 035097 FRAME: 0153. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:MAGANA CASTRO, JOSE AGUSTIN ROGELIO;VAZQUEZ CERVANTES, LAURA;PENA SANTOYO, PEDRO;REEL/FRAME:047248/0212

Effective date: 20150224

AS Assignment

Owner name: EXCALIBUR PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRUPO MEDIFARMA S.A. DE C.V.;REEL/FRAME:053418/0721

Effective date: 20200608

AS Assignment

Owner name: EXCALIBUR PHARMACEUTICALS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRUPO MEDIFARMA S.A. DE C.V.;REEL/FRAME:055388/0266

Effective date: 20200608